SCHEMBL19083735

SCHEMBL19083735

CC(=O)N[C@H](C(=O)O)C1CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
ALOX15 P16050 1/20 0.39
NFKB1 P19838 1/20 0.39
PTGS2 P35354 1/20 0.39
THPO P40225 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
ALDH1A1 P00352 2/20 0.38
EPHX2 P34913 1/20 0.33
CRBN Q96SW2 1/20 0.33
MMP2 P08253 2/20 0.33
MMP3 P08254 2/20 0.33
MMP13 P45452 2/20 0.33
PYGL P06737 2/20 0.32
TGFBR1 P36897 1/20 0.31
CYP2C9 P11712 1/20 0.31
PREP P48147 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13544389 1.00 SMN1; SMN2 (0.39) SMN1; SMN2KDM4EMAPTTHRBALOX15
SCHEMBL31730569 1.00 SMN1; SMN2 (0.39) SMN1; SMN2KDM4EMAPTTHRBALOX15
SCHEMBL10442216 0.91 SMN1; SMN2 (0.41) SMN1; SMN2KDM4EMAPTTHRBALOX15
SCHEMBL19083902 0.91 SMN1; SMN2 (0.37) SMN1; SMN2KDM4EMAPTTHRBALOX15
SCHEMBL10445869 0.91 SMN1; SMN2 (0.41) SMN1; SMN2KDM4EMAPTTHRBALOX15
SCHEMBL19083742 0.91 SMN1; SMN2 (0.37) SMN1; SMN2KDM4EMAPTTHRBALOX15
SCHEMBL9800441 0.90 KDM4E (0.33) SMN1; SMN2KDM4EMAPTTHRBALOX15
SCHEMBL9800440 0.90 KDM4E (0.33) SMN1; SMN2KDM4EMAPTTHRBALOX15
SCHEMBL329758 0.90 MMP2 (0.41) SMN1; SMN2ALDH1A1MMP2MMP3MMP13
SCHEMBL3285856 0.90 MMP2 (0.41) SMN1; SMN2ALDH1A1MMP2MMP3MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. (US) 2023-08-17 US disclosed
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. (US) 2023-08-17 US disclosed
US-11667645-B2 Granzyme B directed imaging and therapy CYTOSITE BIOPHARMA INC. (US) 2023-06-06 US disclosed
US-11667645-B2 Granzyme B directed imaging and therapy CYTOSITE BIOPHARMA INC. (US) 2023-06-06 US disclosed
US-20200369673-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. 2020-11-26 US disclosed
EP-3166939-B1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2019-06-05 EP disclosed
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF RDX, C1R, MTX1 SMN1; SMN2 2803/4885KDM4E 2958/4885MAPT 4404/4885
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB SMN1; SMN2 1756/4885KDM4E 4784/4885MAPT 4766/4885
US-20200369673-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB SMN1; SMN2 1756/4885KDM4E 4784/4885MAPT 4766/4885
US-11667645-B2 Granzyme B directed imaging and therapy GZMB, PRF1, CTSB SMN1; SMN2 1756/4885KDM4E 4784/4885MAPT 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.